Promid trial ppt

Furthermore, it is unclear how many patient had progressing disease on study entry, despite this factor was stratified at randomisation. Firstly, the proliferative behaviour of NETs when lanreotide was stopped after 96 weeks.

Did the patients experience accelerated tumour growth or continuing tumour control? Secondly, did patients on placebo crossed over to octreotide LAR and did tumour achieve control with octroetide salvage? Thirdly, if eventually no overall survival advantage is demonstrated with lanreotide, does this PFS advantage matter? Both patients and clinicians will however need to decide whether this delay in radiographic disease progression is a worthwhile clinical gain.

Secondary endpoints were the percentage of patients who died or showed PD and safety. Computed tomography CT scans taken at baseline and at restaging timepoints throughout the study were centrally assessed. Overall, the therapy was observed to be well tolerated in the trial as well as at Levine Cancer Institute, since its inception, said Kadakia.

Moreover, updated data from the ASCO Annual Meeting seemed to favor Lutathera in terms of quality of life compared with high-dose octreotide. April 4, Caroline Seymour. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group.

J Clin Oncol. After 6 months of treatment, stable disease was observed in Functionally active and inactive tumors responded similarly. The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor.

Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively. Eigler T. Somatostatin system: Molecular mechanisms regulating anterior pituitary hormones. Patel Y. Somatostatin and its receptor family.

Bloom S. Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Rorsman P. The somatostatin-secreting pancreatic delta-cell in health and disease. Mandarino L. Selective effects of somatostatin, and on in vitro insulin and glucagon secretion. Ohnishi H.

Inhibition by somatostatin of amylase secretion induced by calcium and cyclic AMP in rat pancreatic acini. Pyronnet S. Antitumor effects of somatostatin. Lopez F. Molecular mechanisms of antiproliferative effect of somatostatin: Involvement of a tyrosine phosphatase. Buscail L. Evers B. Endogenous cholecystokinin regulates growth of human cholangiocarcinoma. Rai U. Therapeutic uses of somatostatin and its analogues: Current view and potential applications. Krulich L. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro.

Brazeau P. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Guillemin R. Somatostatin: The beginnings, Harris A. Somatostatin and somatostatin analogues: Pharmacokinetics and pharmacodynamic effects. Pradayrol L. N-terminally extended somatostatin: The primary structure of somatostatin FEBS Lett. Zabel B. High-resolution chromosomal localization of human genes for amylase, proopiomelanocortin, somatostatin, and a DNA fragment D3S1 by in situ hybridization.

Msaouel P. Somatostatin and somatostatin receptors: Implications for neoplastic growth and cancer biology. Expert Opin.

Shen L. Bauer W. SMS A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. Berardi R. Medical treatment for gastro-entero-pancreatic neuroendocrine tumours.

World J. Yamada Y. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney.

Lamberts S. Gahete M. Are somatostatin and cortistatin two siblings in regulating endocrine secretions? In vitro work ahead. Jacobs S. Intracellular trafficking of somatostatin receptors. Guillermet-Guibert J. Physiology of somatostatin receptors. Theodoropoulou M.

Somatostatin receptors: From signaling to clinical practice. Florio T. Grozinsky-Glasberg S. Somatostatin analogues in the control of neuroendocrine tumours: Efficacy and mechanisms. Hasskarl J. Somatostatin receptors in non-neuroendocrine malignancies: The potential role of somatostatin analogs in solid tumors.

Future Oncol. Mizutani G. Acta Histochem. Papotti M. Expression of somatostatin receptor types 1—5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. Halperin D. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: A population-based study. Lancet Oncol.

Thorson A. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart pulmonary stenosis and tricuspid regurgitation without septal defects , peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome.

Heart J. Pernow B. Paroxysmal flushing and other symptoms caused by 5-hydroxytryptamine and histamine in patients with malignant tumours. Scholte A. Zur Pathol. Oates J. Pavel M. Cella D. Hofland J.